Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR‐ABL1 positive and BCR‐ABL1 negative myeloproliferative neoplasms workshop
Open Access
- 14 June 2011
- journal article
- abstracts
- Published by Wiley in American Journal of Hematology
- Vol. 86 (9) , 811-819
Abstract
This report is based on the presentations and discussions at the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms (MPN) workshop, which took place immediately following the 52nd American Society of Hematology (ASH) meeting in Orlando, Florida on December 7th-8th, 2011. Relevant data which was presented at the ASH meeting as well as all other recent publications were presented and discussed at the workshop. This report covers front-line therapies of BCR-ABL1-positive leukemias, in addition to addressing some topical biological, pre-clinical and clinical issues, such as new insights into genomic instability and resistance to tyrosine kinase inhibitors (TKIs), risk stratification and optimizing molecular monitoring. A report pertaining to the new therapies and other pertinent preclinical and clinical issues in the BCR-ABL1 negative MPNs is published separately.Keywords
This publication has 130 references indexed in Scilit:
- Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036Cancer Cell, 2011
- Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With ImatinibJNCI: Journal of the National Cancer Institute, 2011
- Navigating the road toward optimal initial therapy for chronic myeloid leukemiaCurrent Opinion in Hematology, 2011
- Chronic myeloid leukemia: mechanisms of blastic transformationJournal of Clinical Investigation, 2010
- Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic PhaseJournal of Clinical Oncology, 2010
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray dataBlood, 2009
- BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repairBlood, 2009
- BCR/ABL and Other Kinases from Chronic Myeloproliferative Disorders Stimulate Single-Strand Annealing, an Unfaithful DNA Double-Strand Break RepairCancer Research, 2008
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006